TICKERNERD
Menu
LQDALQDAHealthcare · Drug Manufacturers - Specialty & Generic

LQDA Stock Forecast: Liquidia Corp. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$26
−6.26% on the day

The 8 Wall Street analysts covering Liquidia Corp. hold a median 12-month price target of $49 — +89.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 6 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$2.5B
Ticker Nerd rank
70 / 100
Median analyst target
$49
Analysts covering
8
Revenue$171.7M+1842.7% y/y
Operating income$85.5M
Net income$74.7M
Free cash flow$68.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−63.3%
1M
−62.3%
YTD
−24.9%
1Y
+13.3%
From 52W high
−71.5%
From 52W low
+17.7%
$22
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LQDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Liquidia Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Growth
99
Value
99
Volatility
72
Momentum
68
Revisions
36
Size
33
Accruals
28
Issuance
18

Quality (100): The business earns solid, repeatable profits on what it owns.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LQDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LQDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26LQDAHigh $72Median $49Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
4 Buy4 Hold0 Sell
Low $30Median $49High $72

The green dot is the last close — the median target sits +89.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
2 Oct 2026HC Wainwright & Co.MaintainsBuy$130 → $58
2 Oct 2026Wells FargoDowngradeEqual-Weight$108 → $30
1 Oct 2026BTIGDowngradeNeutral—
1 Oct 2026NeedhamMaintainsBuy$110 → $72
1 Oct 2026Raymond JamesDowngradeOutperform$106 → $53
13 Aug 2026B of A SecuritiesMaintainsNeutral$79 → $92
13 Aug 2026Wells FargoMaintainsOverweight$62 → $108
12 Aug 2026BTIGMaintainsBuy$109 → $111
12 Aug 2026LifeSci CapitalDowngradeMarket Perform$90
12 Aug 2026NeedhamMaintainsBuy$70 → $110
23 July 2026HC Wainwright & Co.MaintainsBuy$75 → $130
29 June 2026B of A SecuritiesDowngradeNeutral$64 → $79
22 June 2026BTIGMaintainsBuy$59 → $109
5 June 2026HC Wainwright & Co.MaintainsBuy$67 → $75
12 May 2026HC Wainwright & Co.MaintainsBuy$55 → $67
12 May 2026Wells FargoMaintainsOverweight$51 → $62
11 May 2026BTIGMaintainsBuy$50 → $59
11 May 2026NeedhamMaintainsBuy$54 → $70
23 Mar 2026Wells FargoMaintainsOverweight$44 → $51
12 Mar 2026OppenheimerMaintainsUnderperform$16 → $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LQDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LQDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Liquidia Corp. returned +13.3% against +17.3% for the S&P 500, dividends included.

LQDA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26LQDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LQDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−24.0%
Analysts raising
0
Analysts cutting
5
Fundamentals

Liquidia Corp. (LQDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.9×

Cheaper than 37% of US stocks

Price / sales
5.5×

Cheaper than 23% of US stocks

Price / book
12.6×

Cheaper than 7% of US stocks

EV / EBITDA
14.0×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
1842.7%

Higher than 99% of US stocks

Earnings growth (YoY)
1842.7%

Higher than 98% of US stocks

Gross margin
93.3%

Higher than 97% of US stocks

Operating margin
49.8%

Higher than 96% of US stocks

Net margin
30.7%

Higher than 90% of US stocks

Returns & dividend
Return on equity
131.8%

Higher than 97% of US stocks

Return on assets
27.0%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Liquidia Corp. (LQDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Liquidia Corp. has a market value of $2.5B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 1842.7% year on year.

  • Net income over the same four quarters: $138.6M, a 30.7% net margin.

  • Diluted earnings per share, trailing twelve months: $1.37.

  • Free cash flow in the twelve months to 30 June 2026: $147.7M.

  • Shares outstanding: 89.1M.

  • Trailing P/E: 19.9×; forward P/E: 11.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Liquidia Corp. employs 216 people — $2.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

LQDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
LQDALiquidia Corp.$2.5B
70
ALVOAlvotech$2.4B
31
PBHPrestige Consumer Healthcare, Inc.$2.2B
60
BHCBausch Health Cos., Inc.$2.2B
98
SUPNSupernus Pharmaceuticals, Inc.$2.5B
80
TRLVTrulieve Cannabis Corp.$2.0B
89
BCRXBioCryst Pharmaceuticals, Inc.$2.0B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Liquidia Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LQDA news & analysis

Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)

PRNewsWire · 5 Oct 2026negative

Levi & Korsinsky has notified investors of a pending investigation into Liquidia after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation also encompasses Liquidia's forecast of more than $1 billion in 2027 net revenue.

Why it matters — LQDA watchers would care because a patent infringement ruling against a key product, combined with a shareholder investigation, could affect the company's financial outlook and legal standing.

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

Zacks Investment Research · 1 Oct 2026negative

Liquidia Corp.'s stock fell 57% following a patent litigation setback against United Therapeutics. The ruling threatens the PH-ILD indication for Yutrepia and creates uncertainty around the company's commercial outlook.

Why it matters — The patent ruling jeopardizes Yutrepia's PH-ILD indication, a key part of Liquidia's commercial pipeline, raising significant uncertainty for investors tracking the company.

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

Zacks Investment Research · 1 Oct 2026negative

United Therapeutics won a key patent ruling against Liquidia in the dispute over Yutrepia. The ruling could potentially limit Yutrepia's use in PH-ILD and reduce competition for United Therapeutics' Tyvaso products.

Why it matters — Liquidia watchers would care because the patent setback could restrict Yutrepia's addressable market for PH-ILD and weaken its competitive position against Tyvaso.

United Therapeutics Won Its Patent War and Liquidia Collapsed

24/7 Wall Street · 1 Oct 2026negative

A court ruling favored United Therapeutics, draining shares of Liquidia, and the pulmonary hypertension company now faces a fight to survive. The legal battle over the future of its drug Yutrepia remains unresolved, however.

Why it matters — Liquidia watchers would care because the patent ruling against the company threatens its Yutrepia prospects and overall viability, though the dispute is not fully settled.

Liquidia slumps after US court rules for United Therapeutics in patent fight

Reuters · 30 Sept 2026negative

A federal judge ruled that Liquidia's lung drug infringes a key patent held by rival United Therapeutics. The ruling prompted Liquidia shares to plunge nearly 50% and dealt a major blow to the treatment's commercial outlook.

Why it matters — The patent ruling directly threatens the commercial viability of Liquidia's key lung drug, which could significantly impact the company's prospects.

FAQ

Frequently asked questions about LQDA stock

What is the LQDA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Liquidia Corp. have a median 12-month price target of $49, with estimates ranging from $30 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LQDA stock a buy right now?

Of the 8 analysts covering Liquidia Corp., 4 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Liquidia Corp. 70 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LQDA?

As at 6 Oct 2026, Liquidia Corp. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will LQDA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +89.1% from the last close, and Ticker Nerd's factor model ranks Liquidia Corp. 70 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LQDA stock forecast for 2030?

No analyst covering Liquidia Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LQDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $72 over the next 12 months.

How has LQDA stock performed over the past year?

Liquidia Corp. returned +13.3% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Liquidia Corp. do?

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats.

What is the latest news on LQDA?

The most recent item we track (PRNewsWire, 5 Oct 2026): "Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)". Levi & Korsinsky has notified investors of a pending investigation into Liquidia after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation also encompasses Liquidia's forecast of more than $1 billion in 2027 net revenue.

Company

About Liquidia Corp.

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats. Liquidia’s work spans product development, manufacturing, and commercialization, giving it a role across the full lifecycle of specialty respiratory medicines. Its marketed and investigational programs are aimed at patients with challenging respiratory and vascular conditions, positioning the company within the rare-disease and specialty pharmaceutical markets. Liquidia Corporation is headquartered in Morrisville, North Carolina.

CEO Dr. Roger A. Jeffs Ph.D. · 216 employees · United States · https://www.liquidia.com